These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35681079)

  • 21. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
    BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
    Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.
    Štancl P; Hamel N; Sigel KM; Foulkes WD; Karlić R; Polak P
    Front Genet; 2022; 13():852159. PubMed ID: 35783256
    [No Abstract]   [Full Text] [Related]  

  • 26. A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score.
    Yang F; Wei W; Li G; Lan Q; Liu X; Gao L; Zhang C; Fan J; Li J
    Front Genet; 2023; 14():1240068. PubMed ID: 37732324
    [No Abstract]   [Full Text] [Related]  

  • 27. expHRD: an individualized, transcriptome-based prediction model for homologous recombination deficiency assessment in cancer.
    Lee JJ; Kang HJ; Kim D; Lim SO; Kim SS; Kim G; Kim S; Lee JK; Kim J
    BMC Bioinformatics; 2024 Jul; 25(1):236. PubMed ID: 38997639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homologous Recombination Deficiency Scar: Mutations and Beyond-Implications for Precision Oncology.
    van der Wiel AMA; Schuitmaker L; Cong Y; Theys J; Van Hoeck A; Vens C; Lambin P; Yaromina A; Dubois LJ
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
    Marquard AM; Eklund AC; Joshi T; Krzystanek M; Favero F; Wang ZC; Richardson AL; Silver DP; Szallasi Z; Birkbak NJ
    Biomark Res; 2015; 3():9. PubMed ID: 26015868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study.
    Loeffler CML; El Nahhas OSM; Muti HS; Seibel T; Cifci D; van Treeck M; Gustav M; Carrero ZI; Gaisa NT; Lehmann KV; Leary A; Selenica P; Reis-Filho JS; Bruechle NO; Kather JN
    medRxiv; 2023 Mar; ():. PubMed ID: 36945540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.
    Tsang ES; Csizmok V; Williamson LM; Pleasance E; Topham JT; Karasinska JM; Titmuss E; Schrader I; Yip S; Tessier-Cloutier B; Mungall K; Ng T; Sun S; Lim HJ; Loree JM; Laskin J; Marra MA; Jones SJM; Schaeffer DF; Renouf DJ
    NPJ Precis Oncol; 2023 Mar; 7(1):31. PubMed ID: 36964191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer.
    Kim SJ; Sota Y; Naoi Y; Honma K; Kagara N; Miyake T; Shimoda M; Tanei T; Seno S; Matsuda H; Noguchi S; Shimazu K
    Transl Oncol; 2021 Feb; 14(2):100986. PubMed ID: 33340887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.
    Liu H; Zhang Z; Chen L; Pang J; Wu H; Liang Z
    Front Oncol; 2021; 11():798173. PubMed ID: 35096598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    Gou R; Dong H; Lin B
    Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
    von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
    Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
    [No Abstract]   [Full Text] [Related]  

  • 40. Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types.
    Loeffler CML; El Nahhas OSM; Muti HS; Carrero ZI; Seibel T; van Treeck M; Cifci D; Gustav M; Bretz K; Gaisa NT; Lehmann KV; Leary A; Selenica P; Reis-Filho JS; Ortiz-Bruechle N; Kather JN
    BMC Biol; 2024 Oct; 22(1):225. PubMed ID: 39379982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.